$ATRA
Atara Biotherapeutics, Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020052503 Filed on November 09, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.83M $19.02M $19.22M
YoY Change -22.03% 12.74% 37.38%
% of Gross Profit
Research & Development $59.88M $53.54M $48.67M
YoY Change 11.85% 23.49% 71.01%
% of Gross Profit
Depreciation & Amortization $2.180M $1.780M $1.650M
YoY Change 22.47% 49.58% 400.0%
% of Gross Profit
Operating Expenses $74.71M $72.56M $67.89M
YoY Change 2.97% 20.48% 138.55%
Operating Profit -$72.56M
YoY Change 20.48%
Interest Expense $360.0K $660.0K $1.630M
YoY Change -45.45% -64.52% 61.39%
% of Operating Profit
Other Income/Expense, Net $661.0K $1.634M
YoY Change -64.44%
Pretax Income -$74.34M -$71.90M -$66.26M
YoY Change 3.4% 23.19% 59.89%
Income Tax $10.00K $0.00
% Of Pretax Income
Net Earnings -$74.35M -$71.90M -$66.26M
YoY Change 3.41% 23.19% 59.88%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$915.9K -$1.309M -$1.437M
COMMON SHARES
Basic Shares Outstanding 53.76M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $327.2M $282.9M $237.5M
YoY Change 15.66% -22.39% -41.69%
Cash & Equivalents $62.62M $94.43M $57.56M
Short-Term Investments $264.6M $188.5M $181.4M
Other Short-Term Assets $12.30M $10.50M $13.30M
YoY Change 17.14% 25.0% 111.11%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $339.4M $293.4M $250.8M
YoY Change 15.67% -21.34% -39.36%
LONG-TERM ASSETS
Property, Plant & Equipment $51.95M $55.70M $72.20M
YoY Change -6.72% -18.45% 24.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.100M $266.0K $1.700M
YoY Change 689.47% -84.35% 30.77%
Total Long-Term Assets $66.10M $71.37M $73.90M
YoY Change -7.38% 2.1% 24.2%
TOTAL ASSETS
Total Short-Term Assets $339.4M $293.4M $250.8M
Total Long-Term Assets $66.10M $71.37M $73.90M
Total Assets $405.5M $364.8M $324.7M
YoY Change 11.16% -17.64% -31.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.200M $5.155M $6.200M
YoY Change 0.87% -16.85% 1.64%
Accrued Expenses $25.60M $20.20M $14.30M
YoY Change 26.73% 56.59% 34.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $300.0K $400.0K
YoY Change
Total Short-Term Liabilities $36.10M $30.71M $25.20M
YoY Change 17.57% 13.73% 20.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $100.0K $200.0K
YoY Change -100.0%
Other Long-Term Liabilities $15.50M $1.105M $1.180M
YoY Change 1302.71% -91.43% -90.85%
Total Long-Term Liabilities $15.50M $1.105M $1.180M
YoY Change 1302.71% -91.43% -90.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.10M $30.71M $25.20M
Total Long-Term Liabilities $15.50M $1.105M $1.180M
Total Liabilities $51.60M $46.34M $40.79M
YoY Change 11.34% 16.15% 20.33%
SHAREHOLDERS EQUITY
Retained Earnings -$1.043B -$739.5M -$593.2M
YoY Change 41.08%
Common Stock $1.058B $877.1M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $353.9M $318.4M $283.9M
YoY Change
Total Liabilities & Shareholders Equity $405.5M $364.8M $324.7M
YoY Change 11.16% -17.64% -31.36%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q1
OPERATING ACTIVITIES
Net Income -$74.35M -$71.90M -$66.26M
YoY Change 3.41% 23.19% 59.88%
Depreciation, Depletion And Amortization $2.180M $1.780M $1.650M
YoY Change 22.47% 49.58% 400.0%
Cash From Operating Activities -$52.96M -$52.15M -$70.20M
YoY Change 1.55% 8.44% 101.6%
INVESTING ACTIVITIES
Capital Expenditures -$500.0K -$1.490M $796.0K
YoY Change -66.44% -66.89% -95.98%
Acquisitions
YoY Change
Other Investing Activities $8.070M -$57.03M $68.39M
YoY Change -114.15% -457.78% -129.72%
Cash From Investing Activities $7.560M -$58.52M $67.60M
YoY Change -112.92% -611.99% -127.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 33.51M 145.9M -1.926M
YoY Change -77.04% -28715.69% -100.65%
NET CHANGE
Cash From Operating Activities -52.96M -52.15M -70.20M
Cash From Investing Activities 7.560M -58.52M 67.60M
Cash From Financing Activities 33.51M 145.9M -1.926M
Net Change In Cash -11.89M 35.27M -4.530M
YoY Change -133.71% -194.89% -140.19%
FREE CASH FLOW
Cash From Operating Activities -$52.96M -$52.15M -$70.20M
Capital Expenditures -$500.0K -$1.490M $796.0K
Free Cash Flow -$52.46M -$50.66M -$71.00M
YoY Change 3.55% 16.22% 29.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-08-01
CY2019Q1 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201602Member
CY2020Q3 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
185000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13255000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-74348000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-283000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
353935000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
338857000
CY2019Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
4575000
CY2019Q1 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
2898000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12269000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-66257000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
378000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
283934000
CY2019Q2 atra Issuance Of Common Stock Net Of Commissions And Offering Costs Value
IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
7630000
CY2019Q2 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
1802000
CY2019Q3 atra Issuance Of Common Stock And Pre Funded Warrants Net Of Offering Costs Value
IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue
140711000
CY2019Q3 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
25000
atra Finance Lease Assets Obtained In Exchange For Lease Obligations
FinanceLeaseAssetsObtainedInExchangeForLeaseObligations
281000
atra Finance Lease Assets Obtained In Exchange For Lease Obligations
FinanceLeaseAssetsObtainedInExchangeForLeaseObligations
0
CY2020Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1395000
CY2020Q1 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
1330000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12644000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-73509000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
252822000
CY2020Q2 atra Issuance Of Common Stock And Pre Funded Warrants Net Of Offering Costs Value
IssuanceOfCommonStockAndPreFundedWarrantsNetOfOfferingCostsValue
189301000
CY2020Q2 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
1904000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13948000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-77456000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
606000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
381125000
CY2019Q3 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
160000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12152000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-71895000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
60000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
318442000
us-gaap Profit Loss
ProfitLoss
-225313000
us-gaap Profit Loss
ProfitLoss
-212480000
us-gaap Share Based Compensation
ShareBasedCompensation
39847000
us-gaap Share Based Compensation
ShareBasedCompensation
39622000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6175000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5174000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-458000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1177000
atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
1100000
atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
768000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-93000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-927000
us-gaap Accretion Expense
AccretionExpense
58000
us-gaap Accretion Expense
AccretionExpense
53000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-717000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1204000
atra Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-886000
atra Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-238000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
209000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-308000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2718000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1527000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
2004000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
2261000
atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
542000
atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-13038000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-459000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-1836000
atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-924000
atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-487000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1104000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-176639000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-176936000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
279192000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
147187000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
199268000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
209379000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3912000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3021000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
161000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-83836000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
59332000
atra Proceeds From Issuance Of Underwritten Public Offering
ProceedsFromIssuanceOfUnderwrittenPublicOffering
189301000
atra Proceeds From Issuance Of Underwritten Public Offering
ProceedsFromIssuanceOfUnderwrittenPublicOffering
140888000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
58045000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12630000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3407000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
4859000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1521000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
6695000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
289000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
345000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-165000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
248778000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
151337000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11697000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
33733000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75711000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62092000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64014000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95825000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
230000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
699000
atra Proceeds From Issuance Of Common Stock Through At The Market Offering Facilities Not Yet Received
ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived
254000
atra Proceeds From Issuance Of Common Stock Through At The Market Offering Facilities Not Yet Received
ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingFacilitiesNotYetReceived
0
atra Receivable For Options Exercised
ReceivableForOptionsExercised
12000
atra Receivable For Options Exercised
ReceivableForOptionsExercised
0
us-gaap Interest Paid Net
InterestPaidNet
50000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1043300000
us-gaap Interest Paid Net
InterestPaidNet
43000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
7000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to clinical trial and other accruals, stock-based compensation expense and income taxes. Actual results could differ materially from those estimates. </p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11316174
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9441699
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
281771000
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
282099000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
214085000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
214199000
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
44550000
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
44749000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
42993000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
43100000
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
326321000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
326848000
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
257078000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
257299000
CY2020Q3 us-gaap Interest Receivable
InterestReceivable
800000
CY2019Q4 us-gaap Interest Receivable
InterestReceivable
900000
atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2019 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
1400000
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
1400000
CY2019Q4 atra Due To Licensors Current And Noncurrent
DueToLicensorsCurrentAndNoncurrent
0
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62620000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74317000
CY2020Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
194000
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
194000
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64014000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75711000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
69571000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
65854000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17617000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11678000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51954000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
54176000
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2200000
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1800000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5200000
CY2020Q3 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2019Q4 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2020Q3 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2019Q4 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2020Q3 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
the exercise price of an option granted to a 10% shareholder cannot be less than 110% of the estimated fair value of the shares on the date of grant. Options granted generally vest over four years and expire in seven to ten years.
atra Shareholder Ownership Percent
ShareholderOwnershipPercent
0.10
CY2020Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17505050
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13255000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12152000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39847000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39622000

Files In Submission

Name View Source Status
0001564590-20-052503-index-headers.html Edgar Link pending
0001564590-20-052503-index.html Edgar Link pending
0001564590-20-052503.txt Edgar Link pending
0001564590-20-052503-xbrl.zip Edgar Link pending
atra-10q_20200930.htm Edgar Link pending
atra-10q_20200930_htm.xml Edgar Link completed
atra-20200930.xsd Edgar Link pending
atra-20200930_cal.xml Edgar Link unprocessable
atra-20200930_def.xml Edgar Link unprocessable
atra-20200930_lab.xml Edgar Link unprocessable
atra-20200930_pre.xml Edgar Link unprocessable
atra-ex101_113.htm Edgar Link pending
atra-ex102_111.htm Edgar Link pending
atra-ex103_87.htm Edgar Link pending
atra-ex104_206.htm Edgar Link pending
atra-ex311_6.htm Edgar Link pending
atra-ex312_8.htm Edgar Link pending
atra-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending